12.8: Case Study McNeil Recalls and FDA Oversight

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    12.8: Case Study McNeil Recalls and FDA Oversight

    In 2008, complaints about a musty odor in certain Tylenol Arthritis products reached McNeil. An odor complaint might initially appear to be a narrow product issue. It was also information that needed a timely, documented investigation: which products were involved, what they had in common, and whether the concern pointed to a wider quality problem. FDA later documented concerns about the timeliness of McNeil’s investigation and reporting.

    By January 2010, the response had become a regulatory concern. A Form FDA 483 issued for McNeil’s Las Piedras facility on January 8 described observations connected with the odor complaints and reporting. A warning letter that month addressed manufacturing violations at the facility. Recalls involving odor and quality concerns affected several OTC brands. To understand the scope, aMcNeil recall timeline and quality lessons.png customer or investigator needed more than a brand name; lot numbers, dosage forms, and dates identified which products were involved.

    A separate problem then drew attention to McNeil’s Fort Washington facility. An April 2010 inspection documented manufacturing and quality-system concerns involving pediatric liquid products. McNeil recalled affected infant and children’s medicines sold under the Tylenol, Motrin, Zyrtec, and Benadryl brands. These concerns involved a different facility and investigation and should not be merged with the earlier odor issue as if they had one demonstrated cause.

    For families using familiar medicines, the recalls created a practical need to identify affected products and understand the recall instructions. For a manufacturer, answering those questions depends on records connecting ingredients, production, packaging, and distribution. This is the quality lesson of the events; the source documents do not establish the experiences of particular families.

    On September 30, 2010, FDA Principal Deputy Commissioner Joshua Sharfstein described McNeil’s quality failures and FDA oversight in testimony before a House committee. The testimony addressed delayed investigations and reporting. It also stated that the information available at that time did not establish an overall direct link between a recalled product and a serious adverse event, including death. That limitation matters: the documented quality failures should not be presented as proof of deaths caused by the recalled medicines.

    In 2011, a federal consent decree imposed requirements on McNeil operations at three facilities. The story had moved from complaints and inspections to court-enforced remediation. The decree illustrates how recurring weaknesses in manufacturing controls, investigation, reporting, and oversight can require a response extending across operations.

    The case does not show that every complaint predicts a major recall. It shows why a quality system needs a reliable way to receive concerns, investigate them, recognize related events, and escalate decisions. Laboratory results are part of that system, but they cannot replace timely communication or management accountability. The historical enforcement record also should not be used as a complete statement of FDA’s current recall authority.

     


    This page titled 12.8: Case Study McNeil Recalls and FDA Oversight was last modified on Sun, 08 Nov 2026 15:06:22 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.